ARTL
Artelo Biosciences·NASDAQ
--
--(--)
--
--(--)
4.83 / 10
Netural
Fund flow metrics are encouraging with a 7.57/10 score and positive trends across block, small, medium, and large orders. This inflow suggests institutional accumulation despite the negative price trend. Analyst coverage is limited to one neutral call from Maxim Group, resulting in a neutral consensus. The combination of positive money flow and a lone neutral analyst view supports a wait-and-observe stance, monitoring whether capital inflows can reverse the current downtrend.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-19
InstitutionMaxim Group
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of ARTL?
- ARTL holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.83/10 (Netural).
